<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="136181">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01916980</url>
  </required_header>
  <id_info>
    <org_study_id>4117-202</org_study_id>
    <nct_id>NCT01916980</nct_id>
  </id_info>
  <brief_title>An Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Eczema/Dermatitis and Dermal Pruritus (MK-4117-202)</brief_title>
  <official_title>A Phase III, Multicenter, Open-Label Long-Term Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects With Eczema/Dermatitis and Dermal Pruritus.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a efficacy and safety study of up to 12 weeks of desolatadine in Japanese
      participants with eczema/dermatitis and dermal pruritus.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from Baseline in pruritus/itch score (sum of daytime and nighttime scores) assessed by investigator at Week 2</measure>
    <time_frame>Baseline and Week 2</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants who experienced at least one adverse event</measure>
    <time_frame>Up to 14 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants who discontinued from study drug due to an adverse event</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in pruritus/itch score (sum of daytime and nighttime scores) assessed by investigator</measure>
    <time_frame>Baseline, Day 3, Week 1, Week 4, Week 6, Week 8, and Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with improvement in the Global Improvement Rate assessed by investigator</measure>
    <time_frame>Baseline, Day 3, Week 1, Week 2, Week 4, Week 6, Week 8, and Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the degree of pruritus recorded by participants</measure>
    <time_frame>Baseline, Day 3, Week 1, Week 2, Week 4, Week 6, Week 8, and Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">94</enrollment>
  <condition>Eczema</condition>
  <condition>Dermatitis</condition>
  <condition>Dermal Pruritus</condition>
  <arm_group>
    <arm_group_label>desloratadine (5 mg or 10 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Desloratadine, 5 mg, orally, once daily, one 5-mg tablet in the evening for up to 12 weeks. After Week 4, the dose of desloratadine can be increased from 5 mg/day up to 10 mg/day (two 5 mg tablets in the evening), if criteria for dose up-titration are met and there is insufficient anti-pruritic efficacy and no safety concern</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desloratadine</intervention_name>
    <description>Desloratadine, 5 mg, orally, once daily, one 5-mg tablet in the evening for up to 12 weeks (Desloratadine, 10 mg/day, orally, once daily, two 5-mg tablets in the evening for up to 8 weeks)</description>
    <arm_group_label>desloratadine (5 mg or 10 mg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eczema/dermatitis (acute eczema, chronic eczema, contact dermatitis, atopic
             dermatitis, nummular eczema, seborrheic dermatitis, asteatotic eczema,
             neurodermatitis, etc. among eczema/dermatitis for which the observation of pruritus
             is appropriate)

          -  Dermal pruritus (generalized dermal pruritus, localized dermal pruritus)

        Exclusion Criteria:

          -  Hypersensitivity to antihistamines or ingredients of a study drug
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 3, 2014</lastchanged_date>
  <firstreceived_date>August 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dermatitis</keyword>
  <keyword>Dermatitis, Atopic</keyword>
  <keyword>Skin Diseases</keyword>
  <keyword>Skin Diseases, Genetic</keyword>
  <keyword>Genetic Diseases, Inborn</keyword>
  <keyword>Skin Diseases, Eczematous</keyword>
  <keyword>Hypersensitivity, Immediate</keyword>
  <keyword>Hypersensitivity</keyword>
  <keyword>Immune System Diseases</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
    <mesh_term>Pruritus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Desloratadine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
